Literature DB >> 33431934

Deciphering the complex circulating immune cell microenvironment in chronic lymphocytic leukaemia using patient similarity networks.

Zuzana Mikulkova1, Gayane Manukyan1,2, Peter Turcsanyi3, Milos Kudelka4, Renata Urbanova3, Jakub Savara4, Eliska Ochodkova4, Yvona Brychtova5, Jan Molinsky6, Martin Simkovic7, David Starostka3,8, Jan Novak9, Ondrej Janca1, Martin Dihel1, Pavlina Ryznerova3, Lekaa Mohammad10, Tomas Papajik3, Eva Kriegova11.   

Abstract

The tissue microenvironment in chronic lymphocytic leukaemia (CLL) plays a key role in the pathogenesis of CLL, but the complex blood microenvironment in CLL has not yet been fully characterised. Therefore, immunophenotyping of circulating immune cells in 244 CLL patients and 52 healthy controls was performed using flow cytometry and analysed by multivariate Patient Similarity Networks (PSNs). Our study revealed high inter-individual heterogeneity in the distribution and activation of bystander immune cells in CLL, depending on the bulk of the CLL cells. High CLL counts were associated with low activation on circulating monocytes and T cells and vice versa. The highest activation of immune cells, particularly of intermediate and non-classical monocytes, was evident in patients treated with novel agents. PSNs revealed a low activation of immune cells in CLL progression, irrespective of IgHV status, Binet stage and TP53 disruption. Patients with high intermediate monocytes (> 5.4%) with low activation were 2.5 times more likely (95% confidence interval 1.421-4.403, P = 0.002) to had shorter time-to-treatment than those with low monocyte counts. Our study demonstrated the association between the activation of circulating immune cells and the bulk of CLL cells. The highest activation of bystander immune cells was detected in patients with slow disease course and in those treated with novel agents. The subset of intermediate monocytes showed predictive value for time-to-treatment in CLL.

Entities:  

Year:  2021        PMID: 33431934      PMCID: PMC7801466          DOI: 10.1038/s41598-020-79121-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  54 in total

1.  Overexpression of HLA-DR is associated with prognosis of glioma patients.

Authors:  Jinfu Diao; Tianbao Xia; Hongwei Zhao; Jialin Liu; Bin Li; Zhiwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.

Authors:  Lenka Kruzova; Petra Schneiderova; Milena Holzerova; Michaela Vatolikova; Martina Divoka; Peter Turcsanyi; Renata Urbanova; Milos Kudelka; Martin Radvansky; Eva Kriegova; Tomas Papajik; Helena Urbankova
Journal:  Leuk Res       Date:  2019-08-16       Impact factor: 3.156

3.  Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163.

Authors:  Izabela Lapuc; Lukasz Bolkun; Andrzej Eljaszewicz; Malgorzata Rusak; Ewa Luksza; Paulina Singh; Paula Miklasz; Jaroslaw Piszcz; Katarzyna Ptaszynska-Kopczynska; Malgorzata Jasiewicz; Karol Kaminski; Milena Dabrowska; Anna Bodzenta-Lukaszyk; Janusz Kloczko; Marcin Moniuszko
Journal:  Oncol Rep       Date:  2015-06-26       Impact factor: 3.906

4.  Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

Authors:  Jaco A C van Bruggen; Anne W J Martens; Joseph A Fraietta; Tom Hofland; Sanne H Tonino; Eric Eldering; Mark-David Levin; Peter J Siska; Sanne Endstra; Jeffrey C Rathmell; Carl H June; David L Porter; J Joseph Melenhorst; Arnon P Kater; Gerritje J W van der Windt
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

5.  The evolving treatment landscape of chronic lymphocytic leukemia.

Authors:  Luana Schiattone; Paolo Ghia; Lydia Scarfò
Journal:  Curr Opin Oncol       Date:  2019-11       Impact factor: 3.645

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation.

Authors:  Rossana Maffei; Jenny Bulgarelli; Stefania Fiorcari; Linda Bertoncelli; Silvia Martinelli; Carla Guarnotta; Ilaria Castelli; Silvia Deaglio; Giulia Debbia; Sara De Biasi; Goretta Bonacorsi; Patrizia Zucchini; Franco Narni; Claudio Tripodo; Mario Luppi; Andrea Cossarizza; Roberto Marasca
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

8.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors:  Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal:  Blood Adv       Date:  2019-09-10

9.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

10.  HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.

Authors:  Diana P Saraiva; António Jacinto; Paula Borralho; Sofia Braga; M Guadalupe Cabral
Journal:  Front Immunol       Date:  2018-11-13       Impact factor: 7.561

View more
  1 in total

1.  Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

Authors:  Alessandra Romano; Claudio Cerchione; Concetta Conticello; Sabina Filetti; Anna Bulla; Annalisa Chiarenza; Vittorio Del Fabro; Salvatore Leotta; Uros Markovic; Giovanna Motta; Marina Parisi; Fabio Stagno; Giuseppe Alberto Palumbo; Francesco Di Raimondo
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.